ARMATA PHARMACEUTICALS, INC. Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount
ARMATA PHARMACEUTICALS, INC. (ARMP) had Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount of $0 as of 2020-09-30, per its 10-Q filed 2020-11-12.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount · last filed 2020-11-12
- 2020-09-30: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
- 2020-06-30: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
- 2020-03-31: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
- 2019-09-30: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
| Period end | Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount |
|---|---|
| 2020-09-30 | $0.00 10-Q · filed 2020-11-12 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-13 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-14 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-12 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-14 |
| 2018-12-31 | $0.00 10-Q · filed 2019-11-12 |
| 2016-12-31 | $0.00 10-K · filed 2017-03-27 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |